Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HMGCR | P04035 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30167444 | 0.97 | TSHR (0.47) | ALDH1A1TSHRFFAR3LCKFYN | |
| SCHEMBL1323784 | 0.97 | TSHR (0.47) | ALDH1A1TSHRFFAR3LCKFYN | |
| SCHEMBL4891665 | 0.97 | TSHR (0.47) | ALDH1A1TSHRFFAR3LCKFYN | |
| SCHEMBL30868398 | 0.97 | TSHR (0.47) | ALDH1A1TSHRFFAR3LCKFYN | |
| Glycerin SCHEMBL3981872 | 0.79 | ALDH1A1 (0.43) | ALDH1A1TSHRLMNA | |
| SCHEMBL354063 | 0.78 | LMNA (0.42) | ALDH1A1TSHRFFAR3LCKFYN | |
| SCHEMBL10949463 | 0.69 | TSHR (0.56) | ALDH1A1TSHRFFAR3LCKFYN | |
| Acetic Acid SCHEMBL10535191 | 0.69 | FFAR3 (0.78) | ALDH1A1TSHRFFAR3LCKFYN | |
| Acetic Acid SCHEMBL11411038 | 0.69 | FFAR3 (0.78) | ALDH1A1TSHRFFAR3LCKFYN | |
| Acetic Acid SCHEMBL10535188 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102971335-A | Reversibly terminating primer extension reagents | BENNER STEVEN ALBERT | 2013-03-13 | — | — | CN | disclosed |
| US-8212020-B2 | Reagents for reversibly terminating primer extension | BENNER STEVEN ALBERT (US) | 2012-07-03 | — | — | US | disclosed |
| US-20110275124-A1 | Reagents for reversibly terminating primer extension | BENNER STEVEN A | 2011-11-10 | — | — | US | disclosed |
| WO-2010110775-A1 | REAGENTS FOR REVERSIBLY TERMINATING PRIMER EXTENSION | BENNER STEVEN ALBERT (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275124-A1 | Reagents for reversibly terminating primer extension | RNGTT, POLRMT, DNTT | ALDH1A1 1206/4885TSHR 672/4885FFAR3 3475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.